Foghorn Therapeutics Inc. (FHTX) Cash Flow Statement
Foghorn Therapeutics Inc. (FHTX) generated -$84.2M of operating cash flow over the twelve months to 2026-06-30, spent $50000 on capital expenditure and had free cash flow of -$84.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FHTXFoghorn Therapeutics Inc.Follow FHTX — free
—
Price chart with a free account
- Market cap
- 118.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -31.3 | -50.3 | 193.6 | -118.1 | -100.4 | -86.1 | -84.2 | |
| Capital expenditure | 16.2 | 3.3 | 1.2 | 1.2 | 0.9 | 0.1 | -0.1 | |
| Free cash flow | -47.5 | -53.6 | 192.4 | -119.3 | -101.3 | -86.1 | -84.3 | |
| Stock-based compensation | 3.0 | 8.4 | 14.3 | 16.2 | 11.9 | 10.4 | — |
USD millions · SEC XBRL
Foghorn Therapeutics Inc. — questions
- What is Foghorn Therapeutics Inc.'s operating cash flow?
- -$84.2M over the twelve months to 2026-06-30.
- How much does Foghorn Therapeutics Inc. spend on capital expenditure?
- $50000 over the twelve months to 2026-06-30.
- What is Foghorn Therapeutics Inc.'s free cash flow?
- -$84.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Foghorn Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.